share_log

Applied Therapeutics Says FDA Unable To Approve Govorestat NDA Due To Clinical Deficiencies; Expects To Submit An NDA Early In Q1 Of 2025

Applied Therapeutics Says FDA Unable To Approve Govorestat NDA Due To Clinical Deficiencies; Expects To Submit An NDA Early In Q1 Of 2025

applied therapeutics表示,由于临床缺陷,FDA无法批准Govorestat的NDA;预计将在2025年第一季度初提交NDA
Benzinga ·  11/27 15:16

Applied Therapeutics Says FDA Unable To Approve Govorestat NDA Due To Clinical Deficiencies; Expects To Submit An NDA Early In Q1 Of 2025

应用治疗学表示,由于临床不足,美国食品药物管理局无法批准Govorestat新药申请; 预计将在2025年第一季度初提交一份新药申请。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发